Compare VYNE & CFND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYNE | CFND |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | |
| Employees | 10 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 23.8M |
| IPO Year | 2017 | 2025 |
| Metric | VYNE | CFND |
|---|---|---|
| Price | $0.68 | $3.55 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 232.7K | 31.9K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $3.18 |
| 52 Week High | $1.96 | $9.67 |
| Indicator | VYNE | CFND |
|---|---|---|
| Relative Strength Index (RSI) | 66.11 | 39.42 |
| Support Level | $0.56 | $3.18 |
| Resistance Level | $0.69 | $4.14 |
| Average True Range (ATR) | 0.02 | 0.19 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 88.82 | 37.66 |
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.